RNase L activators and antisense oligonucleotides effective to treat RSV infections

• US 6,214,805 B1
• Filed: 11/03/1997
• Issued: 04/10/2001
• Est. Priority Date: 02/15/1996
• Status: Expired due to Fees

• Current Assignee: Cleveland Clinic Foundation, Government of the United States of America
• Original Assignee: Cleveland Clinic Foundation, United States Department Of Health And Human Services
• Inventors: Xiao, Wei, Player, Mark R., Silverman, Robert Hugh, Cirino, Nick Mario, Li, Guiying, Torrence, Paul F.
• Primary Examiner(s): Schwartzman, Robert A.
• Assistant Examiner(s): LARSON, THOMAS GEORGE
• Application Number:
  US08/962,690
• Time in Patent Office: 1,254 Days
• Field of Search: 435/6, 435/375, 514/44, 536/24.3, 536/24.32, 536/24.5, 536/25.2
• US Class Current: 514/44.00A
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/549 Sugars, nucleosides, nucleotides or nucleic acids
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C07H 21/00 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• CPC Class Codes: C12N 15/1131 against viruses
• CPC Class Codes: C12N 2310/31 of the backbone
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/341 Gapmers, i.e. of the type ===---===
• CPC Class Codes: C12N 2310/3521 Methyl

Abstract

The present invention relates to methods of inhibiting infection by RNA viruses with complexes of an activator of RNase L and an oligonucleotide that is capable of binding to the genome, antigenome or mRNAs of a negative strand RNA virus to specifically cleave the genomic or antigenomic RNA strand of the virus. In accordance with the present invention, the methods and complexes of the invention may be applied to target any negative strand RNA virus. The invention in one embodiment relates to a covalently linked complex of an oligonucleotide that is capable of binding to the genomic or antigenomic template RNA strand of a negative strand RNA virus and/or binding to an mRNA of a viral protein (an “antisense oligonucleotide”) coupled to an activator of RNase L. In a preferred embodiment of the present invention, the oligonucleotide component of the complex is complementary to a region of the viral genomic RNA strand characterized by repeated or consensus sequences.

Claims

1. A composition comprising:

a) an oligonucleotide, comprising at least one 2′

O methyl nucleotide, in which the oligonucleotide is complementary to between 15 and 20 nucleotides of a conserved gene-start or gene-end-signal of a genomic RNA strand of a Respiratory Syncytial Virus and a terminus of the oligonucleotide is attached to a linker; and

b) an activator of RNase L attached to the linker.

2. The composition of claim 1 in which the activator is selected from the group consisting of sp5′

A2′

(p5′

A2′

)₂—

O—

, sp5′

A2′

(p5′

A2′

)₃—

O—

, p5′

A2′

(p5′

A2′

)₂—

O—

, and p5′

A2′

(p5′

A2′

)₃—

O—

.

3. The composition of claim 1 in which the oligonucleotide is blocked by a blocker selected from the group consisting of a -p3′

N5′

nucleotide, a p-O-alkylamine, a p-O-hydroxyalkylamine, a sp-O-alkylamine, a sp-O-hydroxyalkylamine, ethyl and methyl.

4. The composition of claim 1 in which the Respiratory Syncytial Virus is the A2 strain, and the portion of the genome is found in conserved regions of gene-start or gene-end signals.

5. The composition of claim 1, in which the oligonucleotide contains one or more phospho-moieties selected from the group consisting of phosphorothioate, methylphosphonate and methylphosphonothioate.

6. The composition of claim 1, in which the oligonucleotide is composed entirely of 2′

O-methyl nucleotides.

7. The composition of claim 1 or claim 6, in which the oligonucleotide is complementary to that portion of the RSV genome comprising the sequence:

3′

CCCCGUUUA 5′

.

8. The composition of claim 1 or claim 6, in which the oligonucleotide is complementary to that portion of the RSV genome comprising the sequence:

3′

CCCUGUUUUA 5′

(SEQ ID NO;

20).

9. The composition of claim 1 or claim 6, in which the oligonucleotide is complementary to that portion of the RSV genome comprising the sequence:

3′

UCAAUUNAUAUAUUUU 5′

(SEQ ID NO;

21).

10. A method of inhibiting Respiratory Syncytial Viral (RSV) infection in a mammalian cell infected with RSV which comprises a step of providing an amount of a complex effective to inhibit RSV infection, said complex comprising:

a) an antisense oligonucleotide, in which the sequence of said oligonucleotide is complementary to between 15 and 20 nucleotides of a conserved region of the genomic RNA strand of a strain of a Respiratory Syncytial Virus and a terminus of the oligonucleotide is attached to a linker; and

b) an activator of RNase L attached to the linker.

12. The method of claim 10 or 11 in which the antisense oligonucleotide is 17 5′

-3′

-linked nucleotides.

11. A method of inhibiting Respiratory Syncytial Viral (RSV) infection in a mammalian cell infected with RSV which comprises a step of providing an amount of a complex effective to inhibit RSV infection, said complex comprising:

a) an antisense oligonucleotide, having a hydroxyl moiety at a first end, in which the sequence of said oligonucleotide is complementary to between about 15 and 20 nucleotides of a normally single stranded portion of the genomic RNA strand of a strain of a Respiratory Syncytial Virus and a terminus of the oligonucleotide is attached to a linker;

b) an activator of RNase L attached to the linker; and

c) a pharmaceutically acceptable, aerosolizable carrier.

13. A composition to inhibit RSV infection in a mammalian cell comprising:

a) an effective concentration of an oligonucleotide, wherein the oligonucleotide comprising at least one 2′

O-methyl modified nucleotide, is between 15 and 20 nucleotides of complementary sequence to a conserved gene-start or gene-end signal of a Respiratory Syncytial Virus genomic RNA strand and is attached to a RNase L activator by a linker; and

b) a pharmaceutically acceptable carrier.

14. The composition of claim 13, which comprises a pharmaceutically acceptable, aerosolizable carrier.

15. The composition of claim 13 which is in a formulation suitable for nasal administration.